Literature DB >> 22543685

Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa: a 3-year prospective study.

S M H Kannenberg1, H F Jordaan, C F N Koegelenberg, F Von Groote-Bidlingmaier, W I Visser.   

Abstract

BACKGROUND: Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson syndrome (SJS) remain feared medication-related reactions. HIV infection and tuberculosis predispose to drug eruptions, yet there is a paucity of data on TEN/SJS in populations with high prevalences of both diseases. AIM: The aim of this prospective observational study was to describe the features and outcomes of patients admitted with TEN/SJS at a large academic hospital in South Africa. We aimed to identify poor prognostic indicators and to validate the use of the TEN-specific severity-of-illness score (SCORTEN) in this population.
METHODS: All patients admitted with TEN/SJS over a 3-year period were enrolled. Disease severity was graded according to percentage skin involved and SCORTEN. Co-morbid diagnoses, clinical features, investigations, complications and outcomes were noted.
RESULTS: 75 patients (39.9 ± 10.6 years, 16 males, 59 HIV positive) were classified as TEN (n  = 42), TEN/SJS overlap (n = 11) and SJS (n = 22). Twenty-four percent died, most from refractory septic shock. Non-survivors had a higher mean SCORTEN on Days 1 and 3 (1.89 vs. 1.04, P = 0.006 and 2.27 vs. 0.90, P < 0.001). A SCORTEN ≥2 on Days 1 and 3 predicted non-survival (OR = 2.94, P = 0.047; OR = 7.45, P < 0.001). Other predictors of non-survival included HIV infection (OR = 6.01, P = 0.058), HIV-tuberculosis co-infection (OR = 8.5, P < 0.001), ≥40% skin involvement (OR = 20.27, P < 0.001), anaemia (OR = 4.68, P = 0.005), hypoalbuminemia (OR = 8.5, P = 0.001) and severe sepsis (OR = 71.09, P < 0.001).
CONCLUSION: Most patients with TEN/SJS were HIV positive and female. We validated the use of SCORTEN and identified several prognostic indicators, most significant being HIV-tuberculosis co-infection, ≥40% skin involvement and severe sepsis.

Entities:  

Mesh:

Year:  2012        PMID: 22543685     DOI: 10.1093/qjmed/hcs078

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  12 in total

1.  Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.

Authors:  Stephen A Goldman
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

2.  Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Hiroshi Chantaphakul; Thanomsak Sanon; Jettanong Klaewsongkram
Journal:  Exp Ther Med       Date:  2015-06-05       Impact factor: 2.447

Review 3.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

4.  The influence of acute kidney injury on the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis: The prognostic value of KDIGO staging.

Authors:  Tao Han Lee; Cheng-Chia Lee; Chau-Yee Ng; Ming-Yang Chang; Su-Wei Chang; Pei-Chun Fan; Wen-Hung Chung; Ya-Chung Tian; Yung-Chang Chen; Chih-Hsiang Chang
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

5.  Outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in HIV-infected patients when using systemic steroids and/or intravenous immunoglobulins in Pietermaritzburg, South Africa.

Authors:  Antoinette V Chateau; Ncoza C Dlova; Halima Dawood; Colleen Aldous
Journal:  South Afr J HIV Med       Date:  2019-07-04       Impact factor: 2.744

6.  Impact of Antibiotics Associated with the Development of Toxic Epidermal Necrolysis on Early and Late-Onset Infectious Complications.

Authors:  Bretislav Lipovy; Jakub Holoubek; Marketa Hanslianova; Michaela Cvanova; Leo Klein; Ivana Grossova; Robert Zajicek; Peter Bukovcan; Jan Koller; Matus Baran; Peter Lengyel; Lukas Eimer; Marie Jandova; Milan Kostal; Pavel Brychta; Petra Borilova Linhartova
Journal:  Microorganisms       Date:  2021-01-19

Review 7.  Vulvovaginal and ocular involvement and treatment in female patients with Stevens-Johnson syndrome and toxic epidermal necrolysis: A review.

Authors:  M Teresa Magone; Mary Maiberger; Janine Clayton; Helena Pasieka
Journal:  Int J Womens Dermatol       Date:  2021-09-02

8.  Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women.

Authors:  Lauren Knight; Gail Todd; Rudzani Muloiwa; Mushi Matjila; Rannakoe J Lehloenya
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

Review 9.  Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective.

Authors:  Bernard Yu-Hor Thong
Journal:  Asia Pac Allergy       Date:  2013-10-31

Review 10.  Epilepsy management in pregnant HIV+ women in sub-Saharan Africa, clinical aspects to consider: a scoping review.

Authors:  Sonia Menon; Lenka Benova; Hillary Mabeya
Journal:  BMC Med       Date:  2020-11-17       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.